TICKERNERD
Menu
ELANELANHealthcare · Drug Manufacturers - Specialty & Generic

ELAN Stock Forecast: Elanco Animal Health, Inc. Price Predictions for 2026-2027

Last close, 6 Oct 2026
$22
−0.13% on the day

The 16 Wall Street analysts covering Elanco Animal Health, Inc. hold a median 12-month price target of $31 — +37.9% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 97 of 100 as at 6 Oct 2026 — among the strongest tenth. Here, the model and the Street point the same way.

Market cap
$11.2B
Ticker Nerd rank
97 / 100
Median analyst target
$31
Analysts covering
16
Revenue$1.4B+10.2% y/y
Operating income$118.0M
Net income$54.0M
Free cash flow$244.0M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−0.6%
1M
−8.2%
YTD
−0.7%
1Y
+8.8%
From 52W high
−16.2%
From 52W low
+13.8%
$20
$27
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

ELAN stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Elanco Animal Health, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 6 Oct 2026
97 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Revisions
97
Value
94
Issuance
82
Quality
81
Accruals
77
Momentum
77
Volatility
64
Growth
62
Size
14

Revisions (97): Analysts have, on balance, been raising their forecasts.

Growth (62): Sales and profits are flat, shrinking, or growing more slowly than they were.

Size (14): Larger than most of the companies we track — more scrutinised, less often mispriced.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

ELAN stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on ELAN, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$20$25$30$35Jan 26Apr 26Jul 26Oct 26ELANHigh $34Median $31Low $26

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says16 analysts
14 Buy2 Hold0 Sell
Low $26Median $31High $34

The green dot is the last close — the median target sits +37.9% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 4 moved their price target up and 0 moved it down.

DateFirmActionRatingTarget
6 Aug 2026KeybancMaintainsOverweight$29 → $30
6 Aug 2026UBSMaintainsBuy$31 → $33
22 July 2026Morgan StanleyMaintainsEqual-Weight$23 → $26
22 July 2026Morgan StanleyMaintainsEqual-Weight—
18 June 2026TD CowenMaintainsBuy—
18 June 2026TD CowenMaintainsBuy$31 → $32
7 May 2026CitigroupMaintainsBuy—
7 May 2026JP MorganMaintainsOverweight—
15 Apr 2026CitigroupInitiatesBuy—
25 Feb 2026KeybancMaintainsOverweight—
25 Feb 2026Morgan StanleyMaintainsEqual-Weight—
24 Feb 2026Leerink PartnersMaintainsOutperform—
19 Feb 2026JP MorganMaintainsOverweight—
22 Jan 2026Piper SandlerUpgradeOverweight—
18 Dec 2025Morgan StanleyMaintainsEqual-Weight—
9 Dec 2025BarclaysInitiatesOverweight—
21 Nov 2025KeybancInitiatesOverweight—
6 Nov 2025UBSMaintainsBuy—
20 Oct 2025UBSMaintainsBuy—
7 Oct 2025JP MorganUpgradeOverweight—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. ELAN appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

ELAN vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 6 Oct 2026, Elanco Animal Health, Inc. returned +8.8% against +17.3% for the S&P 500, dividends included.

ELAN vs S&P 500, last 12 monthsTotal return, rebased to 100
90100110120130Jan 26Apr 26Jul 26Oct 26ELANS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

ELAN analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
EPS revision, 90 days
+6.5%
Analysts raising
13
Analysts cutting
0
Fundamentals

Elanco Animal Health, Inc. (ELAN) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
377.1×

Cheaper than 2% of US stocks

Price / sales
2.2×

Cheaper than 49% of US stocks

Price / book
1.7×

Cheaper than 50% of US stocks

EV / EBITDA
14.8×

Cheaper than 23% of US stocks

Growth & margins
Revenue growth (YoY)
10.2%

Higher than 52% of US stocks

Earnings growth (YoY)
390.9%

Higher than 94% of US stocks

Gross margin
58.3%

Higher than 72% of US stocks

Operating margin
8.6%

Higher than 62% of US stocks

Net margin
−4.0%

Higher than 25% of US stocks

Returns & dividend
Return on equity
−3.0%

Higher than 41% of US stocks

Return on assets
1.6%

Higher than 55% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Elanco Animal Health, Inc. (ELAN) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Elanco Animal Health, Inc. has a market value of $11.2B and an enterprise value of $14.9B.

  • Revenue in the twelve months to 30 June 2026: $5.0B. The latest quarter grew 10.2% year on year.

  • Net income over the same four quarters: −$199.0M, a −4.0% net margin.

  • Diluted earnings per share, trailing twelve months: $−0.41.

  • Free cash flow in the twelve months to 30 June 2026: $379.0M.

  • Shares outstanding: 499.5M.

  • Trailing P/E: 377.1×; forward P/E: 17.5× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • Elanco Animal Health, Inc. employs 9,400 people — $534K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 7 Oct 2026

Data provided by Twelve Data

Peers

ELAN vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelDrug Manufacturers - Specialty & Generic
CompanyMarket capTKN rank
ELANElanco Animal Health, Inc.$11.2B
97
NBIXNeurocrine Biosciences, Inc.$14.5B
87
ALKSAlkermes Plc$6.9B
61
HIMSHims & Hers Health, Inc.$6.9B
17
LNTHLantheus Holdings, Inc.$6.5B
89
AMRXAmneal Pharmaceuticals, Inc.$6.4B
83
VTRSViatris, Inc.$20.2B
100

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Elanco Animal Health, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest ELAN news & analysis

Elanco Animal Health Eyes Growth, Deleveraging as Quattro and Zenrelia Gain Ground

MarketBeat · 26 Sept 2026positive

Elanco Animal Health President and CEO Jeff Simmons outlined the company's growth strategy, product launches, deleveraging plans, and outlook for its pet health and farm animal businesses during the Bank of America Healthcare Conference in London. The presentation highlighted momentum for products including Quattro and Zenrelia.

Why it matters — ELAN watchers would care because the CEO's remarks offer direct insight into the company's strategic direction, new product traction, and debt-reduction plans for both its animal health segments.

Elanco Animal Health Incorporated (ELAN) Presents at Bank of America Global Healthcare Conference 2026 Transcript

Seeking Alpha · 22 Sept 2026neutral

Elanco Animal Health, Inc. (ELAN) presented at the Bank of America Global Healthcare Conference 2026, with a transcript of the presentation published by Seeking Alpha. The company participated in the investor conference session.

Why it matters — An ELAN watcher would care because the conference presentation gives management a platform to discuss the company's business and strategy directly with investors and analysts.

Elanco to Participate in BofA Securities Global Healthcare Conference 2026

PRNewsWire · 17 Sept 2026neutral

Elanco Animal Health announced it will attend the BofA Securities Global Healthcare Conference 2026, scheduled for September 22, 2026. The announcement was made from Indianapolis on September 17, 2026.

Why it matters — A conference appearance gives Elanco a platform to engage with investors and present updates on its business to the financial community.

Expanding Tick and Itch Season Supports Momentum in Elanco Innovation, Meeting Pet Owner Demand for Health and Wellness Care

PRNewsWire · 15 Sept 2026positive

Elanco reports that expanding tick and itch season is supporting momentum for its innovation, driving growth in its base business and overall share gains. The company confirms its U.S. Pet Health segment is on track with expectations for high-single-digit to low-double-digit growth in the second half of 2026.

Why it matters — An ELAN watcher would care because it signals that pet health demand and pest-protection innovation are strengthening the company's core business and market position.

FAQ

Frequently asked questions about ELAN stock

What is the ELAN stock price forecast for 2026-2027?

The 16 Wall Street analysts covering Elanco Animal Health, Inc. have a median 12-month price target of $31, with estimates ranging from $26 to $34. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is ELAN stock a buy right now?

Of the 16 analysts covering Elanco Animal Health, Inc., 14 rate it a Buy, 2 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Elanco Animal Health, Inc. 97 out of 100 across roughly 4,600 US stocks as at 6 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank ELAN?

As at 6 Oct 2026, Elanco Animal Health, Inc. ranks 97 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Revisions (97 of 100).

Will ELAN stock go up?

No one can know that. What the data says: the median 12-month target from 16 analysts implies +37.9% from the last close, and Ticker Nerd's factor model ranks Elanco Animal Health, Inc. 97 out of 100 as at 6 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the ELAN stock forecast for 2030?

No analyst covering Elanco Animal Health, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ELAN are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $26 to $34 over the next 12 months.

How has ELAN stock performed over the past year?

Elanco Animal Health, Inc. returned +8.8% over the 12 months to 6 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Elanco Animal Health, Inc. do?

Elanco Animal Health Incorporated is an animal health company focused on developing, manufacturing, and marketing products for pets and farm animals. Its portfolio includes treatments and preventive solutions for parasitic control, dermatology, pain management, vaccines, and other therapeutic areas used in companion animals and livestock.

What is the latest news on ELAN?

The most recent item we track (MarketBeat, 26 Sept 2026): "Elanco Animal Health Eyes Growth, Deleveraging as Quattro and Zenrelia Gain Ground". Elanco Animal Health President and CEO Jeff Simmons outlined the company's growth strategy, product launches, deleveraging plans, and outlook for its pet health and farm animal businesses during the Bank of America Healthcare Conference in London. The presentation highlighted momentum for products including Quattro and Zenrelia.

Company

About Elanco Animal Health, Inc.

Elanco Animal Health Incorporated is an animal health company focused on developing, manufacturing, and marketing products for pets and farm animals. Its portfolio includes treatments and preventive solutions for parasitic control, dermatology, pain management, vaccines, and other therapeutic areas used in companion animals and livestock. The company serves veterinarians, pet owners, farmers, and producers across a wide range of species, including dogs, cats, cattle, poultry, swine, and sheep. Elanco Animal Health Incorporated also offers products used in food-animal health and production settings, supporting disease prevention and animal wellbeing in everyday care and commercial agriculture. Headquartered in Indianapolis, Indiana, Elanco Animal Health Incorporated operates as a diversified participant in the global animal health market, with a broad product mix spanning companion animal and farm animal care.

CEO Mr. Jeffrey N. Simmons · 9,400 employees · United States · https://www.elanco.com